Converge Biotech Tuesday, August 4, 2020 9:30AM IST (4:00AM GMT)   Converge Biotech Announces the Launch of Vergiflu (Favipiravir 200 mg) in India to Treat Mild to Moderate Covid-19   Hyderabad, India Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India. It will be marketed under the brand name ‘VERGIFLU’ and is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.  

Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India. It will be marketed under the brand name VERGIFLUand is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.

We are delighted to announce the launch of Vergiflu for treatment of mild to moderate COVID-19 patients. At a time when cases are witnessing an alarming trend, our accelerated launch is aimed towards offering patients in India a much needed and timely therapy option. This strengthens our portfolio and keeps our commitment of bringing affordable therapy, accessible to patients,” said Managing Director of Converge Biotech Pvt Ltd, Arun Kumar Bijjala.

Favipiravir is an off patent; broad spectrum oral anti-viral drug backed by strong clinical evidence and has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms. The drug is already approved for novel or re-emerging pandemic influenza virus infection in Japan since 2014, where high recovery rates have been reported with both 7 and 14 days of therapy in both mild and moderate patients. The drug has shorter viral clearance and faster recovery rate and is reported to have a wide therapeutic safety margin for COVID-19 dose.

The mechanism of action of Favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells. The drug has high affinity to RNA virus specific RNA polymerase and gets converted into an active phosphoribosylated form (favipiravir-RTP) in cells thereby inhibiting RNA polymerase activity.

The product is available from today in all major hospitals across the country. It will be sold only on prescription and the company will make sure that the drug is available to the patients.

Converge Biotech also has Prabinex HD (Injection vitamins c 1.5 g), Doxiverge (Inj Doxycycline 100 mg) and Oxihalt (Inj Glutathione 600mg) for hospitalised patients along with immunity boosters, Prabinex 500 mg (Tab Vitamin C 500mg) and Prabinex Z (Tab Vitamin C 500mg with Zinc 20mg); Divify (Vitamin D3 strips) and Tancyvit (Multivitamin).
About CONVERGE BIOTECH 

Converge Biotech is a leading healthcare company based at Hyderabad, having a nationwide presence. It has a strong foothold in the cardio-diabetic and critical care segment, with focus on providing high quality and affordable generic drugs to the patients. Converge Biotech aspires to become the CHANGE agents in the healthcare industry by providing breakthrough treatments with focus on quality, innovation and affordability. All products offered by the company are produced in WHO GMP certified facilities and are audited by dedicated quality and pharmacovigilance team to ensure compliance to stringent quality measures.

Converge Biotech was recognised as the fastest growing company in 2017. In the same year, the company also became ISO 9001:2008 certified, making it the youngest company to reach that milestone. The company received the prestigious Emerging Entrepreneur award in 2019. For more information on Converge Biotech, please visit https://convergebio.in/

  Media Contact Details

Kiran Proddutoori, PR Manager Converge Biotech Pvt Ltd, ,+91-9676625744
, marketing@convergebio.com

Multimedia Gallery

Image Caption : Arun Kumar Bijjala – Managing Director (Converge Biotech) with Vergiflu click for high-res image